NASDAQ:CMRX - Nasdaq - US16934W1062 - Common Stock - Currency: USD
We recently published a list of Why These 15 Healthcare Stocks Are Surging in 2025. In this article, we are going to take a look at where Nutex Health Inc. (NASDAQ:NUTX) stands against other healthcare stocks that are surging in 2025. After lagging behind the broader market in 2024, many healthcare stocks are making a […]
We recently published a list of Why These 15 Healthcare Stocks Are Surging in 2025. In this article, we are going to take a look at where Chimerix Inc. (NASDAQ:CMRX) stands against other healthcare stocks that are surging in 2025. After lagging behind the broader market in 2024, many healthcare stocks are making a comeback […]
We recently published a list of Why These 15 Healthcare Stocks Are Surging in 2025. In this article, we are going to take a look at where agilon health, inc. (NYSE:AGL) stands against other healthcare stocks that are surging in 2025. After lagging behind the broader market in 2024, many healthcare stocks are making a […]
We recently published a list of Why These 15 Healthcare Stocks Are Surging in 2025. In this article, we are going to take a look at where Journey Medical Corporation (NASDAQ:DERM) stands against other healthcare stocks that are surging in 2025. After lagging behind the broader market in 2024, many healthcare stocks are making a […]
Not your typical cannabis play. Discover why Jazz Pharma's FDA-approved CBD drug could make it a top cannabis stock to watch in 2025.
We recently published a list of 11 Best Performing NASDAQ Stocks So Far in 2025. In this article, we are going to take a look at where Chimerix Inc. (NASDAQ:CMRX) stands against other best performing NASDAQ stocks so far in 2025. On March 29, T. Rowe Price portfolio manager Tony Wang appeared on CNBC’s ‘Closing […]
We recently published a list of 11 Best Performing NASDAQ Stocks So Far in 2025. In this article, we are going to take a look at where ThredUp Inc. (NASDAQ:TDUP) stands against other best performing NASDAQ stocks so far in 2025. On March 29, T. Rowe Price portfolio manager Tony Wang appeared on CNBC’s ‘Closing […]
New Drug Application (NDA) for Dordaviprone as Treatment for Recurrent H3 K27M-Mutant Diffuse Glioma Under Review with Prescription Drug User Fee Act...
DURHAM, N.C., March 07, 2025 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), today announced that on March 2, 2025, the Compensation Committee of Chimerix’s...
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
Mentions: GLYC
-Dordaviprone addresses a significant unmet patient need for patients with rare, high-grade brain tumors- -Transaction to add near-term commercial...
Mentions: JAZZ
DURHAM, N.C., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), today announced that on February 12, 2025, the Compensation Committee of...
DURHAM, N.C., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ: CMRX), a biopharmaceutical company whose mission it is to develop medicines that...